Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...

Researchers conducted a post hoc analysis of the SURMOUNT-1 trial to assess the effect of tirzepatide on kidney function in prediabetes with obesity or overweight.

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Combining ASC47 with semaglutide, the new therapy aims to reshape obesity treatment with targeted, once-monthly injections.

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

The game-changing weight loss jabs have ushered in a new era in the war on obesity, but have also been linked to other health ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...